StageZero Life Sciences (TSXV:SZLS.H) Piotroski F-Score: 0 (As of Jun. 25, 2026)


TSXV:SZLS.H StageZero Life Sciences Ltd TSXV:SZLS.H
10 GF Score
Price C$0.04
View Full Analysis

What is StageZero Life Sciences Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

StageZero Life Sciences has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for StageZero Life Sciences's Piotroski F-Score or its related term are showing as below:

StageZero Life Sciences  (TSXV:SZLS.H) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


StageZero Life Sciences Piotroski F-Score Related Terms


StageZero Life Sciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Piotroski F-Score Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 3.00 5.00 3.00 2.00

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 3.00 3.00 3.00
TSXV:SZLS.H
10GF Score
StageZero Life Sciences Ltd TSXV:SZLS.H
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Jun23) TTM:
Net Income was -1.112 + -0.522 + -0.889 + -0.54 = C$-3.06 Mil.
Cash Flow from Operations was 0.065 + -0.126 + -0.086 + 0.014 = C$-0.13 Mil.
Revenue was 1.008 + 0.707 + 0.534 + 0.677 = C$2.93 Mil.
Gross Profit was 0.227 + 0.409 + 0.011 + -0.095 = C$0.55 Mil.
Average Total Assets from the begining of this year (Jun23)
to the end of this year (Sep24) was
(1.042 + 0.687 + 0.513 + 0.8 + 0.787) / 5 = C$0.7658 Mil.
Total Assets at the begining of this year (Jun23) was C$1.04 Mil.
Long-Term Debt & Capital Lease Obligation was C$1.36 Mil.
Total Current Assets was C$0.32 Mil.
Total Current Liabilities was C$13.99 Mil.
Net Income was -0.06 + -12.903 + -2.479 + -0.534 = C$-15.98 Mil.

Revenue was 1.066 + 0.918 + 1.066 + 1.054 = C$4.10 Mil.
Gross Profit was 0.184 + -0.565 + 0.478 + 0.162 = C$0.26 Mil.
Average Total Assets from the begining of last year (Jun22)
to the end of last year (Jun23) was
(11.093 + 11.211 + 0.952 + 0.936 + 1.042) / 5 = C$5.0468 Mil.
Total Assets at the begining of last year (Jun22) was C$11.09 Mil.
Long-Term Debt & Capital Lease Obligation was C$0.94 Mil.
Total Current Assets was C$0.60 Mil.
Total Current Liabilities was C$10.58 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

StageZero Life Sciences's current Net Income (TTM) was -3.06. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

StageZero Life Sciences's current Cash Flow from Operations (TTM) was -0.13. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun23)
=-3.063/1.042
=-2.93953935

ROA (Last Year)=Net Income/Total Assets (Jun22)
=-15.976/11.093
=-1.44018751

StageZero Life Sciences's return on assets of this year was -2.93953935. StageZero Life Sciences's return on assets of last year was -1.44018751. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

StageZero Life Sciences's current Net Income (TTM) was -3.06. StageZero Life Sciences's current Cash Flow from Operations (TTM) was -0.13. ==> -0.13 > -3.06 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Sep24
=1.357/0.7658
=1.77200313

Gearing (Last Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=0.943/5.0468
=0.18685107

StageZero Life Sciences's gearing of this year was 1.77200313. StageZero Life Sciences's gearing of last year was 0.18685107. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=0.318/13.988
=0.02273377

Current Ratio (Last Year: Jun23)=Total Current Assets/Total Current Liabilities
=0.597/10.576
=0.05644856

StageZero Life Sciences's current ratio of this year was 0.02273377. StageZero Life Sciences's current ratio of last year was 0.05644856. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

StageZero Life Sciences's number of shares in issue this year was 123.533. StageZero Life Sciences's number of shares in issue last year was 122.717. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.552/2.926
=0.18865345

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.259/4.104
=0.06310916

StageZero Life Sciences's gross margin of this year was 0.18865345. StageZero Life Sciences's gross margin of last year was 0.06310916. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun23)
=2.926/1.042
=2.80806142

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun22)
=4.104/11.093
=0.36996304

StageZero Life Sciences's asset turnover of this year was 2.80806142. StageZero Life Sciences's asset turnover of last year was 0.36996304. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

StageZero Life Sciences has an F-score of 3. It is a bad or low score, which usually implies poor business operation.


StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for TSXV:SZLS.H

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.04
Price